Equities

Marinus Pharmaceuticals

Marinus Pharmaceuticals

Actions
  • Price (MXN)124.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Apr 15 2024 19:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments150241123
Total Receivables, Net3.806.353.19
Total Inventory2.410.08--
Prepaid expenses8.755.405.57
Other current assets, total------
Total current assets165252132
Property, plant & equipment, net4.845.544.20
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.821.600.96
Total assets171260137
LIABILITIES
Accounts payable4.004.463.13
Accrued expenses232016
Notes payable/short-term debt000
Current portion long-term debt/capital leases12----
Other current liabilities, total2.211.0221
Total current liabilities412541
Total long term debt617141
Total debt737141
Deferred income tax------
Minority interest------
Other liabilities, total52471.98
Total liabilities15414483
SHAREHOLDERS EQUITY
Common stock0.060.050.04
Additional paid-in capital589542460
Retained earnings (accumulated deficit)(572)(431)(411)
Treasury stock - common--00
Unrealized gain (loss)------
Other equity, total(0.02)----
Total equity1711653
Total liabilities & shareholders' equity171260137
Total common shares outstanding555037
Treasury shares - common primary issue0.010.010.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.